A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Conditions

• Graves' Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• IMVT-1402 — DRUG
  Dose 1 for up to 52 weeks

Study Details

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Key Dates

Start date

Jan 26, 2026

Status verified

Jun 2026

Primary completion

Mar 31, 2030

Completion

Mar 31, 2030

Study Design

Enrollment

372 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Group A
• No Intervention: Group B
• No Intervention: Group C

Primary Outcome Measure

Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402 [ Time Frame: At Week 52 ]

Locations (89)

Find similar trials in Phoenix, AZ

Related Studies

• A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
  PHASE2 · Recruiting · Immunovant Sciences GmbH · Phoenix, Arizona
• A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
  PHASE2 · Recruiting · Immunovant Sciences GmbH · Tucson, Arizona
• Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
  PHASE2 · Recruiting · Northwell Health · New Hyde Park, New York